The Cleveland Clinic Foundation

A Cleveland Clinic study of 3,932 patients found that metabolic surgery reduced all-cause mortality by 32% compared to GLP-1 receptor agonist treatment over a median 5.9-year follow-up period.

Over 60% of patients receiving KSI-101 at top dose levels achieved 3-line or more vision gains in the Phase 1b APEX study for macular edema secondary to inflammation.

The ALONE-AF trial demonstrated that discontinuing oral anticoagulant therapy one year after successful atrial fibrillation ablation resulted in significantly lower rates of stroke, systemic embolism, and major bleeding compared to continuing therapy.

The phase III ODYSSEY-HCM trial involving 580 patients showed mavacamten did not significantly improve symptoms or exercise capacity compared to placebo in non-obstructive hypertrophic cardiomyopathy patients at 48 weeks.

Cleveland Clinic has launched Dyania Health's Synapsis AI platform across its clinical research enterprise following successful pilot programs in cardiology, oncology, and neurology.

iMDx has enrolled its first patient in the GraftAssureDx clinical trial, an observational study designed to validate a kitted transplant rejection monitoring test for kidney transplant recipients.

NeOnc Technologies received FDA authorization to proceed with Phase IIa/IIb clinical trial of NEO212, a first-in-class oral chemical conjugated chemotherapy candidate for brain cancer.

Retension Pharmaceuticals completed a $15 million Series B financing round to advance RTN-001, a novel PDE5 inhibitor designed for uncontrolled and resistant hypertension treatment.

Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.

LifePlus announced clinical validation of LifeLeaf®, the world's first non-invasive wearable for continuous glucose and blood pressure tracking, tested at Mayo Clinic, Cleveland Clinic, and other global centers.